Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54


Prevalence and determinants of vitamin D deficiency in infants and toddlers in the Netherlands: a pilot study.

Hoevenaar-Blom MP, Wielders JP, Groeneveld H, de Leeuw E, Schmits RJ, Pepermans C, Pasker-de Jong PC, Hogeman PH.

Ann Clin Biochem. 2019 Sep;56(5):613-618. doi: 10.1177/0004563219857772. Epub 2019 Jul 2. No abstract available.


Epitaxy of advanced nanowire quantum devices.

Gazibegovic S, Car D, Zhang H, Balk SC, Logan JA, de Moor MWA, Cassidy MC, Schmits R, Xu D, Wang G, Krogstrup P, Op Het Veld RLM, Zuo K, Vos Y, Shen J, Bouman D, Shojaei B, Pennachio D, Lee JS, van Veldhoven PJ, Koelling S, Verheijen MA, Kouwenhoven LP, Palmstrøm CJ, Bakkers EPAM.

Nature. 2017 Aug 23;548(7668):434-438. doi: 10.1038/nature23468.


Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study.

Knauf W, Tapprich C, Schlag R, Schütz S, Alkemper B, Gaede B, Reschke D, Schmits R, Schwarzer A.

Oncol Res Treat. 2015;38(4):167-73. doi: 10.1159/000381297. Epub 2015 Mar 31.


Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks.

van Boeckel PG, Dua KS, Weusten BL, Schmits RJ, Surapaneni N, Timmer R, Vleggaar FP, Siersema PD.

BMC Gastroenterol. 2012 Feb 29;12:19. doi: 10.1186/1471-230X-12-19.


Characterization of a photonic strain sensor in silicon-on-insulator technology.

Westerveld WJ, Pozo J, Harmsma PJ, Schmits R, Tabak E, van den Dool TC, Leinders SM, van Dongen KW, Urbach HP, Yousefi M.

Opt Lett. 2012 Feb 15;37(4):479-81. doi: 10.1364/OL.37.000479.


Simvastatin does not prevent acute cardiac allograft rejection in CD28-deficient mice.

Schramm R, Schmits R, Schäfers HJ, Menger MD.

Inflamm Res. 2009 Nov;58(11):765-71. doi: 10.1007/s00011-009-0045-3. Epub 2009 May 6.


Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.


Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.

Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2008 Mar;19(3):538-44. doi: 10.1093/annonc/mdm497. Epub 2008 Jan 22.


Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.

Ziepert M, Schmits R, Trümper L, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2008 Apr;19(4):752-62. Epub 2007 Nov 28.


Role of PECAM-1 in acute rejection of fully major histocompatibility complex class II-mismatched cardiac allografts in mice.

Schramm R, Menger MD, Schmits R, Harder Y, Kirsch S, Meier C, Schäfers HJ.

Transplantation. 2007 Aug 27;84(4):555-8.


Statins inhibit lymphocyte homing to peripheral lymph nodes.

Schramm R, Menger MD, Harder Y, Schmits R, Adam O, Weitz-Schmidt G, Schäfers HJ.

Immunology. 2007 Mar;120(3):315-24. Epub 2006 Nov 28.


The cervical lymph node preparation: a novel approach to study lymphocyte homing by intravital microscopy.

Schramm R, Schäfers HJ, Harder Y, Schmits R, Thorlacius H, Menger MD.

Inflamm Res. 2006 Apr;55(4):160-7.


Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).

Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M.

J Clin Oncol. 2005 Oct 1;23(28):7050-9. Epub 2005 Aug 29.


Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M.

Blood. 2005 Dec 1;106(12):3725-32. Epub 2005 Aug 25.


Advances in molecular biology diagnostic and treatment of B-cell malignancies.

Schmits R, Hartmann F, Pfreundschuh M.

Ann Oncol. 2005;16 Suppl 2:ii105. No abstract available.


The best treatment for diffuse large B-cell lymphoma: a German perspective.

Schmits R, Schmitz N, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):16-25. Review.


Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.

Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9.


Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group.

Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11.


Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group.

Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24.


Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2003 Jun;14(6):881-93.


Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.

Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, König J, Pistorius G, Schilling M, Renner C, Pfreundschuh M.

Hum Gene Ther. 2002 May 1;13(7):815-27.


Absence of the CD44 gene prevents sarcoma metastasis.

Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW.

Cancer Res. 2002 Apr 15;62(8):2281-6.


Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica.

Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M.

Clin Exp Immunol. 2002 Feb;127(2):379-85.


Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas.

Schmits R, Cochlovius B, Treitz G, Regitz E, Ketter R, Preuss KD, Romeike BF, Pfreundschuh M.

Int J Cancer. 2002 Mar 1;98(1):73-7.


Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.

Schmits R, Glass B, Trümper L, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group.

Ann Hematol. 2001;80 Suppl 3:B77-83. Review. No abstract available.


4. Report on workshop: UICC workshop "Therapy of NHL in early stages". Part 2: Aggressive lymphomas.

Schmits R, Trümper L.

Ann Hematol. 2001;80 Suppl 3:B16-9. No abstract available.


Lack of in vivo function of CD31 in vascular thrombosis.

Vollmar B, Schmits R, Kunz D, Menger MD.

Thromb Haemost. 2001 Jan;85(1):160-4.


Participation of leukocyte function-associated antigen-1 and NK cells in the homing of thymic CD8+NKT cells to the liver.

Emoto M, Miyamoto M, Namba K, Schmits R, Van Rooijen N, Kita E, Kaufmann SH.

Eur J Immunol. 2000 Oct;30(10):3049-56.


Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.

Kubuschok B, Cochlovius C, Jung W, Schmits R, Trümper L, Hartmann F, Renner C, Pfreundschuh M.

Cancer Gene Ther. 2000 Sep;7(9):1231-40.


Lymphocyte function antigen 1 (LFA-1) mediates early tumour necrosis factor alpha-induced leucocyte adhesion in venules.

Thorlacius H, Vollmar B, Guo Y, Mak TW, Pfreundschuh MM, Menger MD, Schmits R.

Br J Haematol. 2000 Aug;110(2):424-9.


Cutting edge: contribution of NK cells to the homing of thymic CD4+NKT cells to the liver.

Miyamoto M, Emoto M, Brinkmann V, van Rooijen N, Schmits R, Kita E, Kaufmann SH.

J Immunol. 2000 Aug 15;165(4):1729-32.


Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2.

Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponenberg DP, Nagarkatti M, Nagarkatti PS.

J Immunol. 1999 Aug 1;163(3):1619-27.


Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells.

Emoto M, Mittrücker HW, Schmits R, Mak TW, Kaufmann SH.

J Immunol. 1999 May 1;162(9):5094-8.


Transendothelial migration and trafficking of leukocytes in LFA-1-deficient mice.

Andrew DP, Spellberg JP, Takimoto H, Schmits R, Mak TW, Zukowski MM.

Eur J Immunol. 1998 Jun;28(6):1959-69.


Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity.

Matsumoto G, Nghiem MP, Nozaki N, Schmits R, Penninger JM.

J Immunol. 1998 Jun 15;160(12):5781-9.


Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation.

Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS.

Immunity. 1997 Oct;7(4):549-57.


CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.

Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard JJ, Ohashi PS, Paige CJ, Gutierrez-Ramos JC, Mak TW.

Blood. 1997 Sep 15;90(6):2217-33.


LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor.

Schmits R, Kündig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, Wakeham A, Shahinian A, van der Heiden A, Bachmann MF, Ohashi PS, Mak TW, Hickstein DD.

J Exp Med. 1996 Apr 1;183(4):1415-26.


Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice.

Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, Wakeham A, Mittruecker HW, Griesser H, Takimoto H, Schmits R, Shahinian A, Ohashi P, Penninger JM, Mak TW.

Cell. 1996 Feb 23;84(4):551-62.


Human neoplasms elicit multiple specific immune responses in the autologous host.

Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3.


T-lymphocyte development and function in gene-targeted mutant mice.

Mittrücker HW, Pfeffer K, Schmits R, Mak TW.

Immunol Rev. 1995 Dec;148:115-50. Review. No abstract available.


MSH2 deficient mice are viable and susceptible to lymphoid tumours.

Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrücker HW, Wakeham A, Liu B, et al.

Nat Genet. 1995 Sep;11(1):64-70.


Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta.

Suzuki H, Kündig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H, et al.

Science. 1995 Jun 9;268(5216):1472-6.


A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.

Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M.

Int J Cancer. 1993 Nov 11;55(5):830-6.


Monoclonal antibody FW6 defines an epitope on alpha 3/4-monofucosylated polylactosaminoglycans expressed by fetal and colon carcinoma-associated mucins.

Hanisch FG, Heimbüchel G, Baldus SE, Uhlenbruck G, Schmits R, Pfreundschuh M, Schwonzen M, Vierbuchen M, Bara J, Peter-Katalinic J.

Cancer Res. 1993 Sep 15;53(18):4367-75.


Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.

Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V, Pfreundschuh M.

Ann Oncol. 1992 Sep;3 Suppl 4:49-52.


The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.

Gause A, Jung W, Keymis S, Schobert I, Scholz R, Schmits R, Diehl V, Pohl C, Hasenclever D, Pfreundschuh M.

Leuk Lymphoma. 1992 Aug;7(5-6):439-47.


Monoclonal antibody FW6 generated against a mucin-carbohydrate of human amniotic fluid recognises a colonic tumour-associated epitope.

Schwonzen M, Schmits R, Baldus SE, Vierbuchen M, Hanisch FG, Pfreundschuh M, Diehl V, Bara J, Uhlenbruck G.

Br J Cancer. 1992 Apr;65(4):559-65.

Supplemental Content

Loading ...
Support Center